http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107595872-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-196 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-706 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2017-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-107595872-B |
| titleOfInvention | Pharmaceutical composition for inhibiting prostate cancer stem cells and application thereof |
| abstract | The invention provides a pharmaceutical composition for inhibiting prostate cancer stem cells, which comprises tomatidine and mefenamic acid, wherein the molar concentration ratio of the tomatidine to the mefenamic acid is 1: 2-10. The invention adopts the reasonable compatibility of the tomatidine and the mefenamic acid with the molar concentration ratio of 1:2-10, and the combination of the tomatidine and the mefenamic acid can effectively inhibit the growth of the prostate cancer stem cells, inhibit the prostate cancer stem cells from forming tumor microspheres and effectively inhibit the capability of the prostate cancer stem cells for forming tumors in vivo; the pharmaceutical composition provided by the invention has a low concentration, can reduce the toxic and side effects of the drugs in actual use, reduces the harm to human bodies, and is expected to become a high-efficiency low-toxicity treatment way for inhibiting the prostate cancer stem cells. |
| priorityDate | 2017-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 32.